References
- Champe PC, Harvey RA, Ferrier DR. Lippincott's Illustrated Reviews: Biochemisty Fourth Edition. 2008. Lippincott Williams & Wilkins.
- Yen JL, McLeod HL. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer. 2007;43:1011–1016.
- Heggie GD, Sommadossi JP, Cross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987;47:2203–2206.
- van Kuilenburg ABP, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil associated toxicity: Identification of new mutations in the DPD gene. Clin Cancer Res. 2000:6:4705–4712.
- Diasio RB, Johnson MR. Dihydropyrimidine dehydrogenase: Its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res. 1999;5:2672–2673.
- van Kuilenburg AB, Meinsma R, Zonnenberg BA, et al. Dihydropyrimidine deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res. 2003:9:4363–4367.
- Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity. J Clin Oncol. 2008;26:2131–2138.
- Lievre A, Bachet J-B, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992–3995.
- Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New Engl J Med. 2008;359:1757–1765.
- Amado RG, Wilf M, Peeters M, et al. Wild-type K-ras is required for panitumumab efficacy in patients with metastaic colorectal cancer. J Clin Oncol. 2008;26:1626–1634.
- Wang Z-Y, Chen Z. Acute promyelocytic leukemia: From highly fatal to highly curable. Blood. 2008:111(5):2505–2515.
- Warrell RP, Frankel SR, Miller Jr WH, et al. Differentiation of acute promyelocytic leukemia with tretinoin (All-trans-retinoic acid). N Engl J Med. 1991;324:1385–1393.
- Tallman MS, Altman JK. Curative strategies in acute promyelocytic leukemia. Hematol. 2008; 391–99.
- Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 2009;113(9):1875–1891.